エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of July 2025
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Announcement relating to update on joint corporate brokers in London |
|
|
|
|
|
|
|
|
|
|
|
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
HUTCHMED (CHINA) LIMITED |
|
|
|
|
|
|
|
|
By: |
/s/ Johnny Cheng |
|
Name: |
Johnny Cheng |
|
Title: |
Chief Financial Officer |
Date: July 2, 2025
3
Exhibit 99.1
Update on Joint Corporate Brokers in London
Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has appointed Deutsche Bank AG (trading as Deutsche Numis) as its joint Corporate Broker in London with immediate effect following the termination of HSBC Bank plc as joint Corporate Broker. Panmure Liberum Limited and Cavendish Capital Markets Limited will continue to act as joint Corporate Brokers in London and Panmure Liberum Limited will continue to act as Nominated Advisor to HUTCHMED in London in respect of the AIM rules.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit www.hutch-med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries |
+852 2121 8200 / ir@hutch-med.com |
|
|
Media Enquiries |
|
FTI Consulting – |
+44 20 3727 1030 / HUTCHMED@fticonsulting.com |
Ben Atwell / Alex Shaw |
+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
Brunswick – Zhou Yi |
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
|
|
Panmure Liberum |
Nominated Advisor and Joint Broker |
Atholl Tweedie / Emma Earl / Rupert Dearden |
+44 20 7886 2500 |
|
|
Cavendish |
Joint Broker |
Geoff Nash / Nigel Birks |
+44 20 7220 0500 |
|
|
Deutsche Numis |
Joint Broker |
Freddie Barnfield / Jeffrey Wong / Duncan Monteith |
+44 20 7260 1000 |